Yoh K, Seto T, Satouchi M, et al
Yoh K, Seto T, Satouchi M, et al. inhibitors (pralsetinib, selpercatinib) demonstrating improved efficiency and a far more advantageous toxicity profile are poised to improve the landscaping of RET-dependent malignancies.…